Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas
Top Cited Papers
- 17 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (9), 2613-2623
- https://doi.org/10.1158/1078-0432.CCR-20-4436
Abstract
Purpose: Copy number-high endometrial carcinomas were described by The Cancer Genome Atlas as high-grade endometrioid and serous cancers showing frequent copy-number alterations (CNA), low mutational burden (i.e., non-hypermutant), near-universal TP53 mutation, and unfavorable clinical outcomes. We sought to investigate and compare the clinicopathologic and molecular characteristics of non-hypermutant TP53-altered endometrial carcinomas of four histologic types. Experimental Design: TP53-mutated endometrial carcinomas, defined as TP53-mutant tumors lacking microsatellite instability or pathogenic POLE mutations, were identified (n = 238) in a cohort of 1,239 endometrial carcinomas subjected to clinical massively parallel sequencing of 410-468 cancer-related genes. Somatic mutations and CNAs (n = 238), and clinicopathologic features were determined (n = 185, initial treatment planning at our institution). Results: TP53-mutated endometrial carcinomas encompassed uterine serous (n = 102, 55.1%), high-grade endometrial carcinoma with ambiguous features/not otherwise specified (EC-NOS; n = 44, 23.8%), endometrioid carcinomas of all tumor grades (n = 28, 15.1%), and clear cell carcinomas (n = 11, 5.9%). PTEN mutations were significantly more frequent in endometrioid carcinomas, SPOP mutations in clear cell carcinomas, and CCNE1 amplification in serous carcinomas/EC-NOS; however, none of these genomic alterations were exclusive to any given histologic type. ERBB2 amplification was present at similar frequencies across TP53-mutated histologic types (7.7%-18.6%). Although overall survival was similar across histologic types, serous carcinomas presented more frequently at stage IV, had more persistent and/or recurrent disease, and reduced disease-free survival. Conclusions: TP53-mutated endometrial carcinomas display clinical and molecular similarities across histologic subtypes. Our data provide evidence to suggest performance of ERBB2 assessment in all TP53-mutated endometrial carcinomas. Given the distinct clinical features of serous carcinomas, histologic classification continues to be relevant.Keywords
Other Versions
Funding Information
- NIH NCI (P30CA008748)
This publication has 50 references indexed in Scilit:
- Histotype-Genotype Correlation in 36 High-grade Endometrial CarcinomasThe American Journal of Surgical Pathology, 2013
- Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomasGynecologic Oncology, 2013
- Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial CarcinomaThe American Journal of Surgical Pathology, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide AnalysesJNCI Journal of the National Cancer Institute, 2012
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancersGenome Biology, 2011
- Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomasThe Journal of Pathology, 2011
- p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomesLaboratory Investigation, 2010
- A Modified Bayes Information Criterion with Applications to the Analysis of Comparative Genomic Hybridization DataBiometrics, 2007
- p53 Overexpression and bcl-2 Persistence in Endometrial Carcinoma: Comparison of Papillary Serous and Endometrioid SubtypesGynecologic Oncology, 1996